Lipid Nanoparticles in Skincare: SLN vs NLC, the Invisible Patch and the 2026 Delivery Evidence

Melasyl Skin Tech Lab — Formula Science

Every few years the skincare industry rediscovers a delivery technology that pharmaceutical science has been quietly refining for three decades. Lipid nanoparticles are the current example. Brands increasingly list “encapsulated retinol” or “NLC-delivered vitamin C” on the front of the pack, yet most formulators can still not say precisely how a solid lipid nanoparticle (SLN) differs from a nanostructured lipid carrier (NLC), or why the difference changes penetration, stability and skin feel. This guide separates the two, explains the mechanism that makes them useful, and reviews what the evidence actually supports in 2026.

Two carriers, one lipid matrix

Both SLNs and NLCs are colloidal particles, typically 50–400 nm, built from a lipid matrix that is solid at body temperature. The distinction is entirely in that matrix. An SLN uses a single solid lipid — glycerol monostearate, tristearin, cetyl palmitate or Compritol 888 ATO — forming a near-perfect crystal lattice. A NLC blends solid and liquid lipids, so the lattice is deliberately “imperfect.” That imperfection is the whole point: a perfect lattice squeezes out guest molecules over time (drug expulsion), whereas the disordered NLC matrix keeps them solubilised (Pardeike, Hommoss & Müller, Int J Pharm, 2009; Müller et al., Adv Drug Deliv Rev, 2007).

The three NLC sub-types formalise this. Type I (imperfect crystal) mixes solid and liquid lipids to create lattice defects that host the active. Type II (multiple/amorphous) overloads the liquid lipid so it phase-separates into nanosized oily pockets inside the solid matrix. Type III (amorphous) uses such a high liquid fraction that the matrix solidifies without crystallising at all, giving the highest loading capacity and the lowest expulsion risk. For lipophilic actives that are difficult to stabilise, the progression from SLN to Type III NLC is essentially a loading-and-retention ladder.

The “invisible patch” and why penetration improves

The clinical behaviour of a lipid nanoparticle comes from two coupled effects. First, the particles fuse with the lipids of the stratum corneum and form a continuous occlusive film — the so-called invisible patch (Wissing, Lippacher & Müller, J Cosmet Sci, 2001). This film reinforces the skin’s own lipid barrier, reduces transepidermal water loss and raises stratum corneum hydration, which in turn increases the partitioning of lipophilic actives into the skin. Second, because the particles are small and in intimate contact with the corneocytes, they deposit the active close to the barrier surface, creating a reservoir from which it diffuses downward.

The definitive proof-of-concept came from Wiemann & Keck (Drug Deliv Transl Res, 2022), who compared an NLC against four classical vehicles — pure oil, an o/w cream, and a nanoemulsion — using matched lipids and emulsifiers. The NLC delivered the best chemical stabilisation, the greatest dermal penetration, and it alone formed a measurable invisible patch; it also gave the highest skin hydration. This matters because it removes the common objection that NLC superiority is an artefact of comparing against unequal formulations.

Do lipid nanoparticles actually deliver actives?

The penetration evidence is strongest for lipophilic actives that are otherwise trapped in the stratum corneum. The clearest cosmetic case is glabridin, the licorice flavonoid whose poor solubility and physicochemical instability limit its brightening use. Chauhan et al. (Current Cosmetic Science, 2022) loaded glabridin into an NLC (GMS solid lipid, olive oil liquid lipid) and obtained a 189 nm particle with 94.6% entrapment; the resulting cream inhibited mushroom tyrosinase by 60.3% versus 52.6% for kojic acid in the same assay. A follow-up licorice study (Hoseinsalari et al., Curr Pharm Des, 2024) co-loaded glabridin- and liquiritin-enriched fractions into an NLC of 185 nm, achieving 79.0% and 69.3% entrapment respectively, a two-stage release profile, efficient in vivo skin penetration, strong anti-tyrosinase activity, and stability up to nine months.

Vitamin E tells a similar story. A 2025 Scientific Reports study co-encapsulated α-tocopherol and α-tocopheryl acetate in an NLC gel; entrapment ran 66–93%, release was burst-then-sustained, and in human volunteers the NLC gel raised skin moisture retention by up to 68% and improved elasticity versus a simple solution gel. Notably, the NLC produced high skin retention with minimal transdermal permeation — the desired profile for a cosmetic active that should stay in the skin, not enter circulation.

The mechanistic ceiling is set by particle size. Smaller NLCs penetrate more effectively: an NLC of 107 nm delivered a rice-husk extract to skin more efficiently than larger counterparts in a 2023 study. But size cuts both ways. A comparative Franz-cell study of flavanone and retinoic acid across SLN, NLC, nanoemulsion, liposome and niosome found that skin absorption rose as the solid-lipid fraction increased (SLN > NLC > nanoemulsion), while niosomes gave the best cutaneous targeting. In other words, more solid lipid means more retention but potentially less flexibility — a real design trade-off, not a marketing footnote.

What the evidence does not yet support

Two caveats belong in any honest formulation brief. First, most dermal NLC data is preclinical — Franz-cell permeation, 3D reconstructed epidermis, or animal models. Head-to-head clinical trials comparing an NLC brightening product against an optimised conventional vehicle are rare. A 2023 reconstructed-human-epidermis study confirmed that an NLC of roughly 200 nm was non-irritant and released retinyl palmitate and α-tocopherol in a controlled manner, but that is safety and delivery, not proven efficacy on pigmentation. Second, encapsulation is not a synonym for penetration: if the particle is larger than the follicular or intercellular route allows, or if the active partitions poorly out of the matrix, the carrier can become a shelf rather than a shuttle. Encapsulation efficiency, release kinetics and skin-deposition data must be measured for the specific active, not assumed from the technology name.

A practical lipid-nanoparticle formulation protocol

1. Pick the matrix by payload, not fashion. Soluble, robust lipophilic actives tolerate an SLN; expulsion-prone or high-dose actives need a Type II/III NLC.
2. Choose food-grade lipids first. Compritol 888 ATO, GMS, tristearin (solid) with Miglyol, oleic acid or caprylic/capric triglyceride (liquid) are the well-documented GRAS backbone.
3. Set the solid:liquid ratio deliberately. Increase liquid lipid to raise loading and cut expulsion; too much liquid risks an unstable amorphous core.
4. Select the process for the active’s heat tolerance. Hot high-pressure homogenisation for robust actives; solvent-emulsification-diffusion or cold homogenisation for thermolabile ones.
5. Stabilise with 1–3% non-ionic surfactant (polysorbate 80, poloxamer 188) and monitor PDI and zeta potential through accelerated storage.
6. Validate release and deposition with an in-vitro release test and a Franz-cell or 3D-epidermis study before claiming any delivery benefit.
7. Confirm preservative compatibility. The added lipid load changes water activity and can partition preservatives, so re-challenge-test the finished dispersion or the gel it is embedded in.

Bottom line

SLN and NLC are not competing brands but two rungs of one design ladder: SLN for a clean, stable, high-retention film, NLC when you need loading capacity and sustained release for a difficult active. The invisible patch is real and measurable, penetration gains are well documented for lipophilic molecules, and the safety profile of physiological lipids is excellent. What remains unproven is the leap from “better deposition” to “better clinical outcome on pigment” — and that is the study a serious brightening formulation still has to run.